ClinicalTrials.gg
RecruitingNCT06928844Updated Apr 16, 2025

Role of Low Dose Injectable Progesterone in Triggering Ovulation

An interventional study of Progesterone and Placebo in Low Dose, Progesterone and Triggering Ovulation, sponsored by The General Authority for Teaching Hospitals and Institutes. Recruiting at 1 site in Egypt. Open to female participants aged 20 Years to 35 Years. Per ClinicalTrials.gov, last updated 2025-04-16.

Sponsored by The General Authority for Teaching Hospitals and Institutes · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
20 Years to 35 Years
Sex
Female
01

Study summary

The aim of this study is to evaluate the role of low dose injectable progesterone in triggering ovulation.

Read the detailed description

Infertility affects approximately 10-15% of couples attempting pregnancy, with no readily identifiable cause found in 15-30% of these patients, resulting in a diagnosis of unexplained infertility.

Kol and Itskovitz-Eldor stated that when using GnRH agonist to trigger ovulation in IVF cycles, the LH surge is associated with a rapid rise of progesterone and the attainment of peak E2 levels through the first 12 h after GnRH agonist administration which is followed by a temporary suppression of progesterone biosynthesis and a gradual drop in E2 levels during the 24 h before follicle aspiration. After oocyte retrieval, a second rise in progesterone and continuous fall in E2 are noted, reflecting transitions from follicular to luteal phase in ovarian steroidogenesis.

Letrozole (LE) is a nonsteroidal, highly selective oral aromatase inhibitor (AI) that inhibits the synthesis of oestrogen and increases the secretion of endogenous gonadotropin by diminishing negative feedback to stimulate ovulation. Currently, letrozole is widely used as an adjunct for IVF cycles.

02

Conditions studied

  • Low Dose
  • Progesterone
  • Triggering Ovulation
03

In context

Lead sponsor

The General Authority for Teaching Hospitals and Institutes is the lead sponsor of 8 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age from 20 to 35 years.
  • Infertile women.
  • Basal follicle-stimulating hormone (FSH) level \<10 mIU/ml.

Exclusion criteria

Exclusion Criteria:

  • Poor ovarian reserve.
  • Immunological disease.
  • Endometriosis.
  • Uterine abnormality.
  • (BMI) >30 kg/m2.
  • Endometrial thickness \<8 or >12 mm on the day of triggering.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Progesterone group

    Women will receive low dose progesterone 5 mg intramuscularly as a study group.

    Drug: Progesterone

  • Placebo comparator
    Control group

    Women will receive placebo as a control group

    Drug: Placebo

Interventions

  • Women will receive low dose progesterone 5 mg intramuscularly as a study group. (Letrozole 2.5 mg/day will be given from cycle day 3 onwards for only 5 days).

  • DrugPlacebo

    Women will receive placebo as a control group. (Placebo 2.5 mg/day will be given from cycle day 3 onwards for only 5 days).

06

What researchers measure

Primary outcomes

  1. Incidence of ovulation rates

    Incidence of ovulation rates will be recorded.

    Time frame: 10-12 days of the menstrual cycle

Secondary outcomes

  1. Follicle stimulating hormone (FSH)levels

    Follicle stimulating hormone (FSH) will be measured on day 3, day 8-10 and day 10-12 of the menstrual cycle, as well as the day of trigger and oocyte retrieval.

    Time frame: 10-12 days of the menstrual cycle

  2. Luteinizing hormone (LH)levels

    Luteinizing hormone (LH) will be measured on day 3, day 8-10 and day 10-12 of the menstrual cycle, as well as the day of trigger and oocyte retrieval).

    Time frame: 10-12 days of the menstrual cycle

  3. Estradiol (E2) levels

    Estradiol (E2) will be measured on day 3, day 8-10 and day 10-12 of the menstrual cycle, as well as the day of trigger and oocyte retrieval.

    Time frame: 10-12 days of the menstrual cycle

  4. Progesterone levels

    Progesterone levels will be measured on day 3, day 8-10 and day 10-12 of the menstrual cycle, as well as the day of trigger and oocyte retrieval.

    Time frame: 10-12 days of the menstrual cycle

  5. Number of oocytes

    Number of oocytes will be recorded. Ovulation monitoring will be done from the last day of the cycle until ovulation occurs approximately in the middle of the cycle.

    Time frame: 8 days of the menstrual cycle

  6. Mature oocytes

    Mature oocytes will be recorded.

    Time frame: 16 days of the menstrual cycle

  7. Clinical pregnancy rate.

    Clinical pregnancy rate will be recorded.

    Time frame: One week late from the previous menstrual cycle

  8. Biochemical pregnancy

    Biochemical pregnancy will be recorded through a blood pregnancy test on the date of the next menstrual period

    Time frame: 16 days of the menstrual cycle

  9. Early miscarriage rate

    Early miscarriage rate will be recorded.

    Time frame: 16 days of the menstrual cycle

07

Study locations

1 of 1 sites recruiting
  • Teaching Hospitals and Institutes
    Cairo, Egypt
    Recruiting
    • Abeer A El Shabasi, MD · Contactabear.elshabacy@gmail.com · 00201223331182
    • Mohamed A Raslan, MD · Principal investigator
    • Mona A Baghdadi, MD · Principal investigator
    • Sayida I El-Dessouki, MD · Principal investigator
    • Eslam M El-Sayed, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Supporting information: Study protocol

Time frame: After the end of study for one year.

Access criteria: The data will be available upon a reasonable request from the corresponding author.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Aug 2025, 3 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2025
First posted
Apr 15, 2025
StartActual
Apr 15, 2025
Primary completionEst.
Aug 1, 2025
CompletionEst.
Aug 1, 2025
Last update
Apr 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06928844
Lead sponsor
The General Authority for Teaching Hospitals and Institutes
Responsible party
Abeer Ali Elshabacy (Assistant Scientific Consultant Obstetrics and Gynecology Benha Teaching Hospital, The General Authority for Teaching Hospitals and Institutes) — Principal investigator
First posted
Apr 15, 2025
Start date
Apr 15, 2025
Primary completion
Aug 1, 2025 (estimated)
Completion
Aug 1, 2025 (estimated)
Last update
Apr 16, 2025

Study contacts

Abeer A El Shabasi, MD
Contact
abear.elshabacy@gmail.com
00201223331182

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Progesterone

Start the discussion